LOC

Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance

Both methicillin sensitive and methicillin resistant Staphylococcus aureus (MSSA, MRSA) can cause invasive and life-threatening infections such as osteomyelitis, septicemia, endocarditis, and pneumonia. Healthcare associated MRSA is of particular clinical importance because it is not only predictably cross resistant to all penicillins and cephalosporins, but is also typically resistant to mu...

Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma

LEXINGTON, Mass.--(BUSINESS WIRE)--Jun 12, 2007 - CriticalTherapeutics, Inc. (Nasdaq: CRTX) today announced the publicationof data from a pivotal Phase III clinical trial of ZYFLO CR(TM)(zileuton) extended-release tablets in the June 2007 issue of theJournal of Asthma. ZYFLO CR was approved by the U.S. Food and DrugAdministration (FDA) on May 30, 2007. Critical Therapeutics,together with it...

FDA Announces Change of Location Notice for Upcoming Advisory Committee Meeting

ROCKVILLE, Md., April 18, 2007--Due to water damage caused byflooding over the weekend, FDA has been forced to change thelocation for the upcoming Antiviral Drugs Advisory Committeemeeting on April 24, 2007 to discuss new drug application formaraviroc 300 milligram tablets. Originally scheduled to be held atthe FDA, Center for Drug Evaluation and Research Advisory CommitteeConference Roo...

Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials

VIENNA, Austria, May 18, 2007 – Intercell AG (VSE,“ICLL”) has been informed by its strategic partnerMerck & Co., Inc. on the results of a Phase I study involvingin total over 120 adult healthy volunteers comparing safety andimmunogenicity of different doses of the Staphylococcus aureusvaccine. The Staphylococcus aureus vaccine is based on a conserved prote...

New Position Statement from The North American Menopause Society Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in Postmenopausal Women

CLEVELAND--(BUSINESS WIRE)--May 10, 2007 - An evaluation of thesafety and effectiveness of local vaginal estrogen therapy for thetreatment of vaginal atrophy, a frequent complaint ofpostmenopausal women, has just been released by The North AmericanMenopause Society (NAMS). Entitled "The role of local vaginalestrogen for treatment of vaginal atrophy in postmenopausal women:2007 position stat...

First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan

Unprecedented Evidence for the Effectiveness of HypertensionTreatment Valsartan in Preventing Cardiovascular Events in JapanesePatients TOKYO, April 26, 2007 /Xinhua-PRNewswire/ -- The clinicaloutcomes of the JIKEI HEART Study, the large-scale clinical trialheaded by the Jikei University School of Medicine, was todaypublished in the internationally renowned medical journal TheLancet. The...

Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine

OSLO, Norway--(BUSINESS WIRE)--Apr 23, 2007 - Affitech AS, thehuman antibody therapeutics company announced today that PeregrinePharmaceuticals, Inc. reported positive in vivo test results of R3,a fully human monoclonal antibody developed by Affitech, in apancreatic cancer model at the recently concluded Centennial AnnualMeeting of the American Association for Cancer Research (AACR). R3has...

Calcium Channel Blocker Adalat GITS Offer Additional Benefits

ACTION-trial shows medical and economic advantages of nifedipineGITS therapy LEVERKUSEN, Germany, March 28, 2007 – Two recentlypublished articles in the Journal of Clinical Epidemiology providefurther evidence that the use of the long-acting calcium channelblocker (CCB) nifedipine GITS (Adalat? GITS) has additionalbenefits beyond its blood pressure lowing effec...

REACH Registry Demonstrates That Multiple Arterial Disease Locations Sharply Increase the Risk of Major CV Events in Outpatients With Atherothrombosis

- The Reduction of Atherothrombosis for Continued Health(REACH) PARIS, March 20, 2007 /PRNewswire/ --The REACH Registry 1-yearresults paper published today in the Journal of the AmericanMedical Association (JAMA) show that outpatients withatherothrombosis have a surprisingly high risk of death or majorcardiovascular illness, especially if more than...